Research programme: breast cancer therapeutics - imMAGE Biotherapeutics

Drug Profile

Research programme: breast cancer therapeutics - imMAGE Biotherapeutics

Alternative Names: DNA based Vaccine/Anti-CTL4 - Immage Biotehrapeutics; DNA based Vaccine/Anti-PD-L1 - Immage Biotehrapeutics; IMT 001

Latest Information Update: 01 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immage Biotherapeutics
  • Class Antineoplastics; Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 28 Nov 2016 ImMAGE Biotherapeutics announces intention to submit IND to US FDA in 2017
  • 28 Sep 2016 Immage Biotherapeutics in-licenses SMARTmid™ vectors technology from PepVax before September 2016 (Immage Therapeutics pipeline, September 2016)
  • 13 Sep 2016 Preclinical trials in Breast cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top